U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07502222) titled 'A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis' on March 25.

Brief Summary: This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of patients with moderate-to-severe atopic dermatitis.

Study Start Date: April 07

Study Type: INTERVENTIONAL

Condition: Moderate-to-Severe Atopic Dermatitis

Intervention: BIOLOGICAL: AK139 and placebo

AK139 plus placebo regimen 1-subcutaneous injection.

BIOLOGICAL: AK139

AK139 regimen 2-subcutaneous injection.

BIOLOGICAL: AK139 and placebo

AK139 plus placebo regimen 3-...